Permacol Paste in Perianal Crohn's Disease (UPpCro)
Use of Permacol Paste in Perianal Crohn's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Annalisa Maroli, PhD
- Phone Number: +390282247776
- Email: annalisa.maroli@humanitas.it
Study Contact Backup
- Name: Francesca Di Candido, MD
- Phone Number: +390282247776
- Email: francesca.di_candido@humanitas.it
Study Locations
-
-
MI
-
Rozzano, MI, Italy, 20089
- Recruiting
- Istituto Clinico Humanitas
-
Contact:
- Annalisa Maroli, PhD
- Phone Number: +390282247776
- Email: annalisa.maroli@humanitas.it
-
Contact:
- Francesca Di Candido, MD
- Phone Number: 0282247776
- Email: francesca.di_candido@humanitas.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18, any sex
- Diagnosis of CD at least 6 months earlier in accordance with clinical, endoscopic, histological an/or radiological criteria
- Presence of perianal fistulas with maximum 3 external openings and a maximum of 2 internal openings, assessed by physical examination and MRI
- Non-active or mildly active luminal CD defined by a CDAI < 220
Exclusion Criteria:
- CDAI > 220
- Dominant luminal active CD requiring immediate surgical or medical therapy
- Fistula with > 3 external openings and > 2 internal openings
- Severe active proctitis and/or rectal stenosis
- Abscess or pelvic collection > 2 cm diameter
- Concomitant rectovaginal fistulas
- Concomitant steroid treatment or treated with steroids in the last 4 weeks
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Perianal Crohn's Disease
Permacol Paste injection
|
Permacol Paste Injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perianal fistula closure rate
Time Frame: 12 months
|
Complete fistula closure will be defined as absence of spontaneous suppuration or suppuration on applying gentle pressure
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients quality of life
Time Frame: 12 months
|
Quality of life will be assessed using the Inflammatory Bowel Disease Quality of Life (IBDQ).
IBDQ is a disease-specific questionnaire included 32 questions.
The questions consisted of 4 domains as follows: Bowel symptoms (10 questions), systemic symptoms (5 questions), emotional functioning (12 questions), and social functioning (5 questions).
Every question score ranged from 1 to 7 which 7 corresponded to the highest level of functioning.
Total score ranged from 32 to 224.
Higher score showed higher quality of life.
|
12 months
|
|
Patients continence
Time Frame: 12 months
|
Continence will be assessed by means of the Cleveland Clinic Incontinence Score (CCIS, or Wexner scale).
This scoring system cross-tabulates frequencies and different anal incontinence presentations (Gas/Liquid/Solid/Pad use/Need for lifestyle alterations) and sums the returned score to a total of 0-20 (where 0 = perfect continence and 20 = complete incontinence).
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.